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Inflammation is often a protective reaction against harmful foreign agents. However, in 
many disease conditions, the mechanisms behind the inflammatory response are poorly 
understood. Often times, the inflammation causes adverse effects, such as joint pain, abdominal 
pain, fever, fatigue, and loss of appetite. Thus, many treatments aim to inhibit the inflammatory 
response in order to control adverse symptoms. Such treatments include TNFα inhibitors. 
However, a major risk associated with drugs inhibiting tumor necrosis factor alpha (TNFα) is 
serious infection, including tuberculosis (TB).  
Anti-TNFα therapy is used to treat patients with Crohn’s disease, for which the risk of 
tuberculosis may be even more concerning. Recent literature suggests Crohn’s might involve 
Mycobacterium avium subspecies paratuberculosis (MAP), an intracellular TB-like bacterium. 
This study seeks to investigate the risk of developing TB in patients with Crohn’s disease treated 
with TNFα inhibitors. A meta-analysis synthesized existing evidence. Evidence came from 
published randomized, double-masked, placebo-controlled trials of TNFα inhibitors for treatment 
of adult Crohn’s disease.  
Twenty-three trials were identified, including 5,669 patients. The risk of tuberculosis was 
significantly increased in anti-TNFα treated patients, with a risk difference of 0.028 (95% 
confidence interval [CI], 0.0011-0.055). The odds ratio was 4.85 (95% CI, 1.02-22.99) when all 
studies were included and 5.85 (95% CI, 1.13-30.38) when studies reporting zero tuberculosis 
cases were excluded. 
The risk of tuberculosis is increased in patients with Crohn’s disease treated with TNFα 
inhibitors. The medical community should be alerted about this risk and the potential for TNFα 
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Inflammation is a vital mechanism to protect against foreign agents. However, in many 
disease conditions, the immune system reacts for reasons that are not entirely understood. Often 
times, the response causes adverse symptoms, as is the case in rheumatoid arthritis, Crohn’s 
disease, ankylosing spondylitis, and psoriasis.1 Thus, many treatments aim to inhibit the 
inflammatory response in order to control adverse symptoms.2 Such treatments include TNFα 
inhibitors. However, a major risk associated with drugs inhibiting tumor necrosis factor alpha 
(TNFα) is serious infection, including tuberculosis (TB).3  
Anti-TNFα therapy is used to treat patients with Crohn’s disease, for which the risk of 
developing TB infection may be even more relevant. Recent literature suggests Crohn’s disease 
involves Mycobacterium avium subspecies paratuberculosis (MAP), an intracellular TB-like 
bacterium.4-6 Thus, this study seeks to investigate the risk of developing TB in patients with 
Crohn’s disease treated with TNFα inhibitors.  
Crohn’s disease has become a global disease with a prevalence reaching 0.32% in 
Western Europe and North America and an increasing incidence in many other parts of the 
world.7 TNFα inhibitors are the recommended therapy to treat moderate to severe Crohn’s 
disease, which has led to a rise in the development of biologic therapeutic drugs.8 As of 2018, 
three TNFα inhibitors (not including biosimilars) have been approved by the European 
Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for treating 





infliximab. The aforementioned anti-TNFα therapy have proven efficacy in relieving symptoms 
and are play an integral role in treatment options for Crohn’s disease.9,10  
However, suppressing the immune system carries many risks. Rare risks, especially, may 
not be characterized and studied well in the trials and investigations leading up to drug approval. 
Individual double-masked, randomized, placebo-controlled trials (RCTs) of TNFα inhibition 
therapy lack the power to analyze and determine whether there are increases in risk for 
developing uncommon adverse reactions, such as cancer or serious infection. However, these 
RCTs provide quality data for meta-analysis. Indeed, meta-analysis has previously demonstrated 
that risk of serious infection was increased for patients suffering from rheumatoid arthritis, 
psoriatic arthritis, and ankylosing spondylitis who elected to use TNFα inhibitors to manage their 
conditions.3 Furthermore, meta-analysis published in 2016 reported a significantly increased of 
opportunistic infections associated with the use of TNFα inhibitors for treatment of Crohn’s 
disease. However, the association between tuberculosis or serious infection and anti-TNFα 
therapy still remained unclear and was not reported.11 A major limitation to current analytical 
methods is the inability to deal with clinical trials reporting zero-event data in both arms of the 
studies (“double-zero studies”). Most often, meta-analytical studies excluded these double-zero 
studies.12,13 As will be discussed later, the number of aforementioned “double-zero studies” is 
high due to the low incidence of tuberculosis. In other scenarios, data from trials with zero-event 
data from just one group were often subject to modification (“continuity correction”) that, while 
having mathematical basis, lacks biological reasoning. Thus, previous analytical approaches cast 
uncertainty about whether or not sufficient evidence indicating an increased risk of developing 





Tuberculosis infection should be provided special attention, as aforementioned, Crohn’s 
disease might be caused by Mycobacterium avium subspecies paratuberculosis (MAP).6 TNFα is 
of special importance due to its ability to contain granulomatous infections as an inflammatory 
cytokine.6 Therefore, TNFα inhibitors can not only to disrupt the human body’s ability to contain 
and deal with tuberculosis but also to MAP, further increasing the patient’s susceptibility to the 
MAP bacterium or even worsen their disease condition.14 Thus, a meta-analysis of RCTs to 
specifically quantify the risk of tuberculosis development in patients who suffer from Crohn’s 




















Concentrations of TNFα have been found to be elevated in the stool, mucosa, and blood 
of patients suffering from inflammatory bowel disease. Thus, monoclonal antibodies to TNFα 
were synthesized to treat and manage the symptoms of patients.8  
Although anti-TNFα therapies have brought great change to the treatment of IBD, there 
are theoretical and realized safety concerns. Case reports often initially raise awareness and need 
for research regarding novel therapies and their unexpected adverse side effects. Often, it is these 
reports that lead to larger powered studies and to hypothesis generation.15 
Large scale studies done on TNFα inhibitors as a whole has discovered that the 
immunosuppressant therapy does increase patient risk of developing infections and even 
cancer.16 Indeed, pharmaceutical companies have funneled large sums of money not only to 
conduct clinical trials but to also explore all the possible consequences of biologic medicines.2 
Previous studies have found increased risk of tuberculosis, opportunistic infections, 
malignancies, and serious infections in various disease groups and over a drug class as a whole. 
In fact, adverse events and side effects from the use of biologics are well documented and well 
known.14 However, many of these studies are outdated, not comprehensive, or cannot deal with 
rare events. Specifically, previous meta-analyses have not investigated whether TNFα inhibitors 
increase TB infection risk in patients suffering from Crohn’s disease.12 Up until 2018, there was 
not enough literature or lake of tools to investigate such a topic. Previous analyses have been 
able to draw conclusions about rheumatoid arthritis and psoriatic disease due to the abundance of 





there was no increased risk of overall infections in patients suffering from CD where were 
treated with TNFα inhibitors versus with placebos.13  
With TNFα inhibitors that are approved relatively recently, there are even less studies 
and data to draw conclusions from. Conversely, recently approved FDA or EMA drugs 
necessitate the greatest amount of scrutiny. These studies often lack the power to draw definitive 
assessments, which makes it difficult to come discover and warn the general public of the 
potential side effects that the therapies may bring.12 
With numerous RCTs of TNFα inhibitors published now, it is possible to draw a more 
accurate conclusion and pooled estimate on the risk of TB infection. In addition, a quantified 


























In an effort to make the data and the work more transparent, this meta-analysis was 
registered online in the prospective register of systematic reviews (PROSPERO) international 
database on February 8th, 2018 (PROSPERO ID: CRD42018087548).18 The following 
methodology adhered closely to the preferred reporting items for systematic reviews and meta-
analyses (PRISMA) checklist (Appendix A).19  
 
Data Source and Search Strategy 
A database search of PubMed was conducted up until January 21, 2018. The search terms 
and methodology used are as follows: biologic(s), tuberculosis, adalimumab, certolizumab, 
infliximab, TNFα inhibitors, anti-TNFα, or TNFα in conjunction with Crohn’s disease. The 
results were restricted to only double-masked, randomized, placebo-controlled trials. 
ClinicalTrials.gov supplemented the search methodology in the event of completed clinical trials 
with unpublished data. Studies that were irrelevant were screened out after reviewing the title 
and abstracts. Studies that made it past the initial screening had their full text and abstracts 
evaluated more closely.  
 
Selection 
Only sources written in English were considered. Studies qualified for inclusion if they 
were randomized, placebo-controlled, double-masked trials with adequate exposure in adult 
populations. Exposure was defined as receiving treatment of TNFα inhibitors (certolizumab 





older) Crohn’s disease by the European Medicines Agency and the U.S. Food and Drug 
Administration. As mentioned in the introduction, non-approved drugs, including those not in 
phase 3 clinical trials, and biosimilars of anti-TNFα therapy were excluded from the meta-
analysis. All drug doses were included in the study. Duplicates and observational studies were 
screened out. Single studies with both an induction and maintenance phase but reported distinct 
patient groups were analyzed as two unique trials.  
 
Data Extraction 
Data was extracted onto a Microsoft Excel spreadsheet. First author, year of publication, 
study duration, number of participants in treatment and control groups, patient characteristics, 
treatment parameters (i.e. TNFα inhibitor and placebo), events in treatment and control groups, 
and screening method were recorded from each study. Studies found via ClinicalTrials.gov were 
also analyzed, with the aforementioned characteristics also recorded. Cases of TB infection was 
the primary outcome assessed in this meta-analysis. TB infection was defined as diagnosis of 
active tuberculosis by the clinician or other medical professional participating in the respective 
clinical trial.  
 
Risk difference 
Arcsine differences (ASD) were used as the measurement of risk differences. For a trial 
with 𝑁" subjects in the anti-TNFα treatment group, 𝑁#  subjects in the control group, and a and b 
(following a standard 2x2 table; table 1) being the number of reported tuberculosis cases, 







 Table 1: Common 2x2 table 
 Event  
Group Yes No Total 
Treatment a b nT 
Control c d nC 
Total a + c b + d n 
 




   (Equation 1) 
The use of arcsine difference for analysis can be dated as far back as the 1940s.20,21 The 
notable advantages to using ASD are that the variance of the point estimate (i.e. 𝐴𝑆𝐷) is 
determined only by the sample size and that it deals with occurrences of 0 counts naturally, 
allowing for trials with 0 events in both arms of the study to be incorporated into meta-















The Yusuf-Peto method calculated odds ratios (ORs).23 Although commonly used, the 
Mantel-Haenszel method was not utilized because it cannot include deal with double-zero studies 
without substituting zero with a non-zero number. The Yusuf-Peto method provides a distinct 
advantage in that it includes single-zero studies; therefore, the Yusuf-Peto odds ratio (𝑂𝑅0123) 
was recognized as a (relatively) more efficient estimator, especially since treatment effects from 
trials are not large in number or the size of samples are similar between two groups.24 The 
𝑂𝑅0123 for an individual trial was calculated according to Equation 2: 
 






      (Equation 2) 






However, the Yusuf-Peto method, once again, cannot deal with double-zero studies. As 
mentioned previously, known approaches used for meta-analysis on TNFα inhibitors are to 
exclude double-zero studies altogether and, in the event of single-zero studies, to change 
recorded zero counts by adding either 0.5 events or a number, usually around 0.5 in magnitude, 
that calculated based on inverse proportions to the relative size of the opposite drug (treatment or 
placebo) group.3,11,25  These analytical treatments lack any basis in biology or epidemiology.  
 
Epidemiologically-Based Background Correction 
Through the exclusion of double-zero studies, the obtained results will be biased away 
from the null hypothesis. Likewise, a continuity correction may bias the results towards the null. 
Thus, an epidemiologically-based background correction (EBC) was proposed and utilized. This 
approach estimated an expected number of cases (e.g., if there was an expected 0.01 tuberculosis 
case from an experimental arm, such a case would very likely not be observed. However, using 
0.01 events to replace a 0 event would more adequately reflect the underlying epidemiology as 
opposed to continuity corrections of around 0.5). The epidemiologically-based background 
correction assumed an incidence of tuberculosis of 20 cases/100,000 person-years, which was the 
incidence reported for patients suffering from inflammatory bowel disease (IBD) in the United 
Kingdom.26 EBC was subsequently calculated according to Equation 3 below.  
 
EBC = n	× Follow up duration (years)× 20 cases
100,000 person-years
   (Equation 3) 
 





The mathematics and reasoning behind the correction will be described in the following 
statements. The number of people in the control or treatment groups was multiplied by the length 
of time of TNFα inhibitor (or placebo) exposure (weeks) to produce exposure length in person-
weeks. This was converted to person-years by dividing by 54 weeks. The converted exposure 
length (person years) was then multiplied by the incidence of TB in the United Kingdom among 
populations with inflammatory bowel disease, which was 20 cases/100,000 person years (Aberra 
et al., 2007). The end result were cases that were less than 1 but greater than zero. This allowed 
for sparse events, such as TB incidence, to be dealt with without using the continuity correction 
of 0.5. The EBC was then calculated and added into event counts recording both tuberculosis and 
non-tuberculosis for clinical trials with zero event occurrences. 
 
Statistical analysis 
Statistical analysis used the intent-to-treat principle. R version 3.4.327, along with the 
“meta” package, was utilized to graph plots and calculate the Yusuf-Peto OR and the ASD along 
with corresponding confidence intervals (manual calculation on a Microsoft Excel spreadsheet 
verified calculation accuracy). Contribution weight from individual studies to the overall, pooled 
estimate was calculated based of the inverse variance of the point estimate from individual 
studies. The DerSimonian-Laird method calculated inter-study variance28. Two-sided P values of 
less than 0.05 with the 95% confidence interval (95% CI) excluding the null was statistically 








The beauty of meta-analysis is its ability to pool multiple low-powered studies to increase 
the overall power and synthesize data to generate a more conclusive conclusion than single 
studies can alone. Such ability to pool data lies heavily in statistics and mathematics. With meta-
analysis, two models are primarily followed: fixed-effects and random effects.28 Under the fixed-
effects model, population groups across studies are assumed to be relatively similar, with little 
variation. Under the random-effects model, populations are assumed to be heterogeneous and 
differ from one study to the next.29 In this investigation, the data synthesis will follow the 
random-effects model, as study participants were not only in different stands but also in different 
countries.  
Thus, the overall point estimate, variance, and confidence intervals were calculated. The 
overall concept remained similar regardless of which whether the ASD or Yusuf-Peto method 
was utilized. Point estimates and variances were generated from each individual study. Weights 
were assigned to studies based on an inverse relationship with the respective variance. Thus, 
studies that had low numbers of study participants tended to have high variances, which 
subsequently lowered their weights. Studies that had many participants had lower variances and, 
subsequently, more weight.30 
The calculations used for the pooled ASD point estimate are as follows.  












where nT and nC are defined as denoted in table 1.  
  
Assume that there are K studies. For k = 1, . . . ,  K, the estimated treatment effect 
for the kth study is 𝜃k, and the standard error of this particular estimate is sk. The 
individual sk is calculated by the following conversion 
 
sk = 𝑣      (Equation 5) 
 




Thus, the overall treatment effect point estimate is provided by 
 




	,     (Equation 6) 
 
and the standard error, SE, is provided by  
  
 SE = >
NLPLQR
 .     (Equation 7) 
 





For an individual study, k, the variance can be estimated by v, where v is 
calculated as 
v = (5S ,5T 6*6-
6;(6=>)
.    (Equation 8) 
and E calculated as  
E =  
((5S)(,5T)
6
     (Equation 9) 
where a, c, b, d, n, nT, and nC are all defined once again by table 1. 




 ,    (Equation 10) 


















Search Results  
From PubMed, a total of 748 articles were located. Titles and abstracts were reviewed to 
determine eligibility. Studies that were clearly not relevant, 706 studies in total, to the meta-
analysis were excluded. The remaining 42 articles were more closely examined to determine 
inclusion in the analysis. Six studies were excluded because they were not head-to-head or 
placebo-controlled, 5 did not study FDA or EMA approved drugs, 4 were not placebo-controlled, 
and 3 studies were duplicates in that they measured the same sample. All-in-all, 19 of the 42 
studies were not included in the analysis. Two additional trials were located through 
clinicaltrials.gov; of which, one (NCT00291668) did not post the results and was excluded. 
Thus, a total of 23 studies were included in the meta-analysis.16,31-51 The selection process was 















Figure 2. Evidence collection and selection 
 
 
The 23 studies evaluated adalimumab (number of studies (n) = 7; 1726 patients), 
certolizumab pegol (n = 6; 2008), and infliximab (n = 10; 1935). For this analysis, both induction 
and maintenance studies were analyzed. A total of 5669 patients were enrolled in the clinical 





patients were in the control group. The treatment arm sizes were mostly similar to control arm 
sizes, with a median ratio being 1.03:1. Nonetheless, some studies had unbalanced arm sizes 
(maximum ratio = 3.32:1, average ratio = 1.64:1). Follow-up duration ranged anywhere from 4 
to 104 weeks (mean follow-up duration = 32 weeks). A grand total of approximately 79,000 
person-years was exposed to either anti-TNFα therapy or placebo throughout the duration of all 
the clinical trials (treatment = 46,000 person-years, control = 33,000 in person-years). Dates of 
publication ranged from 1997 to 2016. Six cases of tuberculosis were recorded, and all of these 
cases were reported in treatment groups. Two cases of TB were recorded in trials using 
adalimumab, 1 using certolizumab pegol, and 3 using infliximab. A summary of the trials’ 
specifics – follow-up duration, treatment, cases, and publication year – is presented in table 2.  
 
Table 2. Summary of randomized, placebo-controlled, double-masked trials included. 







 n N n N 
Adalimumab      
Hanauer et al., 200647 4 0 225 0 74 
Colombel et al., 200750 52 2 517 0 261 
Sandborn et al., 2007a38 52 0 37 0 18 





Rutgeerts et al., 201240 48 0 64 0 65 
Watanabe et al., 201232 52 0 25 0 25 
Watanabe et al., 201232 4 0 67 0 23 
  Total: 1094  632 
Certolizumab Pegol      
Winter et al., 200431 12 0 66 0 24 
Schreiber et al., 200533 20 0 145 0 73 
Sandborn et al., 2007c39 26 0 331 0 329 
Schreiber et al., 200734 20 1 216 0 212 
Sandborn et al., 201136 6 0 223 0 215 
NCT00349752, 201445 36 0 87 0 87 
  Total: 1068  940 
Infliximab      
Targan et al., 199716 12 0 83 0 25 
D’Haens et al., 199949 4 0 22 0 8 
Present et al., 199944 18 0 63 0 31 
Rutgeerts et al., 199941 36 0 37 0 36 





Sands et al., 200435 40 0 139 0 143 
Lémann et al., 200646 52 0 57 0 58 
Colombel et al., 201051 30 1 169 0 170 
Regueiro et al., 201143 52 0 11 0 13 
Regueiro et al., 201642 104 1 147 0 150 
  Total: 1113  822 
 
Risk Difference 
The risk difference between anti-TNFα therapy and placebo was found to be 0.028 (95% 
CI, 0.0011-0.055; P < 0.05) (Table 3). The random-effect model results are presented for the 
ASD. The fixed effects results for the Peto OR are also presented, although the inter-study 
variance did not additionally contribute to the total variance of the pooled OR (the DerSimonian-
Laird estimate of between study variance was zero).  
 







Risk difference 23 0.028 (0.0011, 0.055) 0.042 
Odds ratio     
Including double-zero studies 23 4.85 (1.02, 22.99) 0.047 








The respective weights for each drug, adalimumab, certolizumab pegol, and infliximab, were 
28.9%, 36.9%, and 34.2%. The risk differences were 0.028, 0.015, and 0.042 respectively 






















Figure 3. Risk difference of tuberculosis infection between patients suffering from 

















The risk difference was calculated via arcsine transformation of TB infection incidence (Arcus Sinus 
Difference, ASD) and was indicated by the numbers on x-axis. Weight indicated the percentage 
contribution of the individual study to the pooled estimation. This weight corresponded to the size of the 
black box. The x-axis indicated risk difference. Vertical dashed line indicated the pooled point estimate. 
Solid horizontal lines described the 95% confidence interval (CI). The solid diamond shows the overall, 
pooled confidence interval for each individual TNFα inhibitor and for the entire study. 
 
A funnel plot of the ASDs (Figure 4) was also graphed, indicating that trials that had 
smaller risk differences were more often published. However, this does not suggest publication 





primary focus of the studies. To the contrary, the funnel plot showed that larger studies had a 
higher likelihood of detecting rare risks (TB infection) than smaller ones.  
 
Figure 4. Relationship between the estimated tuberculosis risk difference and the 
corresponding standard error of the estimate.  
 
The center, dashed vertical line indicated the pooled calculated. The diagonal lines indicated the respective 
95% confidence intervals associated with the expected mean ASD for clinical trials enrolling a variable 
number of study subjects. 
 
Relative odds 
The treatment arm sizes were comparable to the control arm sizes. A median ratio of 
treatment arm size to control arm size was calculated at 1.03. However, specific studies had 
particularly unbalanced arm sizes, with a maximum ratio of 3.32:1 and an average ratio = 1.64:1.  
The odds ratio was calculated at 4.85 (95% CI, 1.02-22.99; P<0.05) with the EBC and 
5.85 (95% CI, 1.13-30.38; P<0.05) without the EBC (Table 3). The random effects model could 
not be used because the Yusuf-Peto odds ratio calculations follows the assumption of a fixed 





18.2%, and 50.7% with EBC, respectively (Figure 5). Without the EBC, only 5 studies could be 

























Figure 5. The odds of patients developing active TB infection when treated with TNFα 
inhibitors for their Crohn’s disease relative to those treated with placebo.  
 
Odds ratio (OR) was calculated using the Yusuf-Peto method and indicated by the numbers on the x-axis. 
Number of tuberculosis infection cases was corrected with a background TB incidence, the EBC. Once 
again, the weight was the percentage contribution of an individual study to the pooled estimation. The size 
of the black box is proportional to the weight of the study. The vertical dashed line indicated the pooled 
odds ratio. The solid horizontal lines show the respective 95% confidence interval (CI). The black diamond 
shows the overall confidence interval for each biologic and for the entire analysis.  
 
Number Needed to Harm 
With a background TB infection incidence in patients equivalent to 20 cases/100,000 person-
years, one active tuberculosis infection case would be expected from a total of 5,000 Crohn’s 
disease patients who do not use TNFα inhibitors within one year. An ASD of 0.028 would mean 





case would be expected when treating 565 patients with anti-TNFα therapy for one year (Table 
4). If the harmful effects of TNFα inhibitors are described on a multiplicative scale, as is the case 
with the pooled Yusuf-Peto odds ratio, the numbers of patients treated to expect 1 tuberculosis 
case can be anywhere from 855 to 1031 (Table 4). 
 
Table 4. Estimated incidence of active TB infection in patients with Crohn’s disease treated with 
anti-TNFα therapy.  
  
Incidence of tuberculosis 
with TNFα treatment 
(cases/person-years) 
Number of patients treated 
to see one tuberculosis 
case in one year 
Based on risk difference 177/100,000 565 
Based on relative odds estimated 
with background correction 
97/100,000 1,031 




The number of patients with Crohn’s disease treated with TNFα inhibitors to expect one active TB infection case is 








This investigation advances the current state of knowledge on the association between 
anti-TNFα therapy and active tuberculosis infection in patients with Crohn’s disease. First, a 
non-biased estimation of active tuberculosis infection risk associated with the use of TNFα 
inhibitors for the treatment of Crohn’s disease was performed by using arcsine transformations 
of tuberculosis infection incidence, which enabled all qualified studies, including double-zero 
studies, to be included in the meta-analysis. Secondly, a novel, epidemiologically-based 
background correction was developed and used to adjust for zero count events, enabling the 
inclusion of double-armed zero event studies into the estimation of the relative effect (odds 
ratio). Finally, with the use of the aforementioned analytical approaches, a significant increase of 
tuberculosis infection risk with the usage of TNFα inhibitors for the treatment of adult Crohn’s 
disease was demonstrated from existing evidence, challenging the findings of previous studies. 
 
Meta-analysis 
In this investigation, all qualified clinical trials with public data were included, 
amounting to 23 studies in total. Among these 23 studies, 18 (78%) had no reported cases of 
tuberculosis infection from either the TNFα inhibitor treatment or the placebo treatment. These 
18 studies would have been excluded if the arcsine difference was not used and had the analysis 
followed methods that previous meta-analyses regarding this particular area of interest took. The 
abundance of double-zero observations was expected. Tuberculosis infection, while a relatively 





South Africa, and Japan, which was where these RCTs were conducted. In meta-analysis, a rare 
event has less than a 1/1,000 chance of occurrence.29 The median sample size of the control 
groups across the 23 studies was 73 people, and the median follow-up duration was 30 weeks. 
About 0.0084 tuberculosis cases would be expected, mathematically, in control group if the 
background tuberculosis followed the incidence of 20 cases/100,000 person-years as reported by 
Aberra et al.26 For reference, if TNFα inhibitors had increased the risk of tuberculosis infection 
by 5 times, there would be about a 4% chance to observe 1 event in the anti-TNFα treatment 
arm. Meta-analysis provides the ability and opportunity to pool multiple studies together to 
increase the probability of observing a single tuberculosis infection case. Furthermore, 
discarding double-zero studies (78% of the studies in our analysis) might decrease the value of 
meta-analysis. 
The risk difference calculated using the arcsine transformation of incidence was 
considered as the primary results. The ASD method does not need any correction for zero-event 
counts. Additionally, the ASD estimate provides another advantage in that it is not contingent on 
the effect size or the balance of sample sizes between the treatment and control groups. These 
analytical features greater utility over either the Yusuf-Peto method or the Mantel-Haenszel 
method. However, a more intuitive understanding of risk of TB infection may be better described 
on a multiplicative scale as a ratio. Thus, further analysis was performed, for which the Yusuf-
Peto method was the approach of choice because, compared to the Mantel-Haenszel method, it 
can handle zero events in single arms.52 Even with non-zero events, the Mantel-Haenszel method 





occurances are less that 1 in 1,000.53 Unfortunately, the Yusuf-Peto method cannot handle 
double-zero studies.  
 
Funnel Plot 
A funnel plot graphing ASDs of the studies (figure 3) versus their standard errors was 
relatively symmetric and followed an inverted funnel shape, showing a low risk of publication 
bias, selective outcome reporting, or selective analysis reporting (Egger et al., 1997). However, it 
is still unclear if funnel plots really diagnose publication bias (Lau et al., 2006). Since risk of TB 
was not the primary reason the clinical trials were conducted, it is more likely that publication 
bias is less of a concern.  
 
Epidemiological Background Correction 
An epidemiologically based background correction (i.e., EBC) was proposed in order to 
mathematically replace zero events. The formula to calculate the corrections was based off the 
exposure length (person-years) and the UK TB incidence rate in IBD populations to produce a 
non-zero number of TB cases. In the event that metrics other than ASD (i.e. odds ratio, hazards 
ratio or rate ratio) are estimated and that the event of interest is so rare that even one occurrence 
would not be expected, the EBC is recommended for continuity corrections instead of adding 
0.5, similar corrections based on the ratio of the sample size between treatment and control 
groups, or statistical-model based estimates.29,30 The latter approaches are not rooted in 
epidemiology and lack biological considerations. In the case of adding 0.5 or a similar modifier, 





example, in this study, it would have boosted the background incidence by about a factor of 60. 
Thus, the common artificial continuity correction was not used was due to its inaccuracy and 
invalid conclusion regarding small sample size, small number of studies, or low event rates.52 
 
Limitations 
All data from all clinical trials were assumed to be available and that no bias due to 
unpromising results not being reported or due to patient withdrawals were present. Additionally, 
if a study did not report TB outcomes, then it was assumed that that there were 0 cases of TB in 
that study. The FDA mandates that serious infections are reported in clinical trials, which TB is 
defined as54. However, it is possible that cases of TB were reported under serious infections or 
opportunistic infections without being reported in the study.  
There are some notable limitations with the use of the EBC. The EBC was based on the 
tuberculosis incidence rate in the UK IBD populations up until 1997, before the first TNFα 
inhibitors were available to the public. In the decades since then, it is possible that TB incidences 
in these UK populations have changed. The reported incidence also takes into account that the 
Crohn’s patients likely used certain medications that increased their risk of infection overall, 
such as corticosteroids. Additionally, although most of the studies were conducted in Western 
countries, the TB infection incidence of Crohn’s patients in the United Kingdom may also not 
truly represent the average TB infection incidence of the countries in which the clinical trials 
were conducted. Furthermore, the TB infection incidence rate was that found in populations with 





Crohn’s disease. Since the correction assumed the incidence of TB is identical with or without 
TNFα inhibitor usage in the clinical trials, the results are also biased towards the null. 
In the TB incidence is closer to that found in the general population in the UK, which is 9 
cases/100,000 person-years, then the double-zero studies included in the meta-analysis would 
have a lower calculated weight.26 That would result in the five studies with reported cases of TB 
infection having a higher contribution to the pooled estimate, leading to an overall ratio that is 
higher (closer to the 8.85 times increased risk) with a larger confidence interval than the Peto OR 
calculated with the determined correction but smaller than the Peto OR calculated without the 
double-zero studies.  
Aside from the approaches to avoid Simpson’s paradox, the ability to pool distinct results 
from individual clinical trials in this meta-analysis resided in the fact that each study had a 
placebo-treatment arm. Therefore, the impact from having different study populations was 
largely minimized, as either the end point (risk difference or odds ratio) mostly reflected the 
effect of TNFα inhibitors alone (the impact of confounders was either subtracted out [for ASD] 
or divided out [for ORs]). Thus, between-study heterogeneity such as geographic location, 
population characteristics, exposure, maintenance vs. induction trials, and screening methods is 
assumed to be minimized. Within study heterogeneity such as age, geographic location, 
exposure, and race is assumed to be reduced by the random assignment of participants to 
treatment and control groups. 
All the studies were in English, so the generalizability of the results may be limited, 
especially considering that the demographics and trends of both Crohn’s disease and tuberculosis 





EMA- and FDA-regulated clinical trials conducted in western countries. In fact, only one study 
that enrolled largely Asian populations was included in this meta-analysis.32 In this regard, EBC 
may also be compromised, since the prevalence and incidence of tuberculosis is higher in Asian 
countries.56 Thus, much caution should be taken when extrapolating and applying results from 




Special attention should be paid to screening. Patients could have had either latent TB 
infection that was reactivated or acquired TB infection through exposure. The screening methods 
varied by trial and often went unreported. Additionally, screening out patients based on a 
positive tuberculin skin test may bias certain patient population groups due to the prevalence of 
BCG vaccinations in non-western countries. Furthermore, screening out patients based on a 
positive tuberculin skin test may have different impacts on the tuberculosis occurrence due to the 
different practices of Bacillus Calmette-Guérin vaccinations.57 Thus, certain study groups may 
have less immigrant participants enrolled. That would therefore lower the expected number of 
TB infection cases. Finally, two studies did not report screening methods.42,48 Closer 
examination of the details of trial screenings may provide additional insight on the nature of TB 









Much still remains uncertain about the etiology Crohn’s disease. Current literature 
suggests that Crohn’s disease might be caused by an immune response to enteric bacteria.58 
Recent research also points to Crohn’s disease being intimately linked with MAP, a TB-like 
bacterium.6 The use of anti-TNFa therapy in these patients could even favor MAP infection and 
worsen the patient condition, which is what was found in this study. Currently, it is difficult to 
come to conclusions about possible linkages, considering that the RCTs did screen or test for 
MAP infection – much less reported it. Additional research could be done on analyzing patient 
outcomes and determining which patients were infected with MAP and their susceptibility to 
overall, serious, or TB infection was.  
Much more research could be done on the EBC. Specifically, mathematically modeling to 
determining the validity of such a correction as compared to previous existing methodologies 
would elucidate the strengths and weaknesses of such an approach. This is not the first time a 
novel correction was introduced. In a 2016 study, Bai et al. used a similar correction that could 
adjust for zero outcomes when events are rare.30 Thus, more needs to be elucidated on the current 
meta-analytical approaches, tools, and corrections so that data from clinical trials can be more 
adequately assessed.  
Additional models can be explored as an avenue to analyze rare event data. The beta-
binomial model holds much promise; however, its programming and transformations can be 
difficult to interpret.21 Nonetheless, future research and analyses could explore and investigate 





Finally, future meta-analysis could analyze other adverse events reported by clinical 
trials. Such topics of interest include risk of serious infection and overall infection. The topic of 
interest could be extended or narrowed. For example, further analysis could be done on anti-
























All in all, this study concluded that there is sufficient evidence to support the association 
between TNFα inhibitors use and an increased the risk of developing tuberculosis in patients 
with Crohn’s disease. Twenty-three studies were analyzed with multiple statistical methods 
consistently providing significant risk. To current knowledge, all these 23 studies represent the 
most comprehensive and appropriate literature available for the topic at hand, with an extensive 
search and careful review conducted. No studies written in English were excluded, provided that 
a placebo control was present and that they were randomized and masked. The randomization of 
patients and clinicians minimized potential confounding agents such as age, duration of IBD, and 
disease activity.  
The results challenge findings from previous studies, which all reported no significantly 
increased risk of tuberculosis infection associated with TNFα inhibitor usage among patients 
with Crohn’s disease.11,13 Based on the pooled risk difference (ASD) calculated in this study, on 
average 565 patients treated with TNFα inhibitors would be expected to result in 1 patient getting 
infected with TB, versus 5000 patients electing therapy other than TNFα inhibitors producing 1 
case of TB, assuming the background incidence of tuberculosis in moderately severe Crohn’s 

















































































Appendix B-1: Arcsine R Code (forest plot and funnel plot) 
dat<-read.csv(file="<file location>", header=TRUE, sep=","); dat; 
CD <- metabin(event.e=ai, n.e=n1, event.c=ci, n.c=n2, data = dat, sm = "ASD", byvar=Drug, 
studlab=paste(Authors), print.byvar=FALSE); CD; 
 
 
pdf(file = "<file location/figure name.pdf>", width = 8.5, height = 11); 
forest(CD, leftcols=c("studlab"), comb.fixed=FALSE, hetstat =FALSE, digits=4, 
col.by="black", col.diamond="black", col.square="black"); dev.off(); 
 
 
jpeg(file=""<file location/figure name.jpeg>", width = 10, height = 10, units = 'in', res = 600); 
forest(CD, leftcols=c("studlab"), comb.fixed=FALSE, hetstat =FALSE, digits=4, 
col.by="black", col.diamond="black", col.square="black"); dev.off(); 
 
 
tiff(file="<file location/figure name.tiff>", width = 10, height = 10, units = 'in', res = 600); 
forest(CD, leftcols=c("studlab"), comb.fixed=FALSE, hetstat =FALSE, digits=4, 
col.by="black", col.diamond="black", col.square="black"); dev.off(); 
 






par(ps = 13, cex = 1.5, cex.main = 1); funnel(CD, bg="black", axes=FALSE); axis(1, at=seq(-

























Appendix B-2: Yusuf-Peto R Code (forest plot) 
dat<-read.csv(file="<file location>","); dat; 
CD <- metabin(event.e=ai, n.e=n1, event.c=ci, n.c=n2, data = dat, sm = "OR", method = "Peto", 
byvar=Drug, studlab=paste(Authors), print.byvar=FALSE); CD; 
pdf(file = "<file location/figure name.pdf>", width = 8.5, height = 11); 
forest(CD, comb.random=FALSE, hetstat =FALSE, col.by="black", col.diamond="black", 
col.square="black", rightcols=c("w.fixed"), xlim=c(0.01, 400), colgap="4mm", digits.weight=3); 
dev.off(); 
 
jpeg(file=""<file location/figure name.jpeg> ",  
width = 10, height = 10, units = 'in', res = 600); 
forest(CD, comb.random=FALSE, hetstat =FALSE, col.by="black", col.diamond="black", 




tiff(file="<file location/figure name.tiff>", width = 10, height = 10, units = 'in', res = 600); 
forest(CD, comb.random=FALSE, hetstat =FALSE, col.by="black", col.diamond="black", 
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